UBE2C and prostate cancer: Neither VT-464 nor abiraterone altered the expression of UBE2C, which is activated by AR in a ligand-independent manner16 in prostate cancer cells, verifying that VT-464 and abiraterone specifically inhibited ligand-dependent AR functions in C4-2B cells.